Thrivent Financial for Lutherans Reduces Stake in Omnicell, Inc. (NASDAQ:OMCL)

Thrivent Financial for Lutherans decreased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 0.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 35,801 shares of the company’s stock after selling 317 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Omnicell were worth $1,594,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its position in shares of Omnicell by 3.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 594,996 shares of the company’s stock valued at $25,942,000 after purchasing an additional 22,198 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Omnicell by 7.7% in the third quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock valued at $1,102,000 after acquiring an additional 1,813 shares during the period. PEAK6 Investments LLC acquired a new stake in shares of Omnicell in the third quarter valued at approximately $448,000. Martingale Asset Management L P purchased a new position in shares of Omnicell during the third quarter worth approximately $507,000. Finally, Walleye Capital LLC increased its holdings in shares of Omnicell by 44.0% in the 3rd quarter. Walleye Capital LLC now owns 18,214 shares of the company’s stock valued at $794,000 after acquiring an additional 5,569 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on OMCL shares. Benchmark restated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Wells Fargo & Company dropped their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Bank of America reduced their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. JPMorgan Chase & Co. lowered their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. Finally, StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Monday, March 24th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $51.00.

Omnicell Trading Down 1.0 %

Shares of Omnicell stock opened at $35.01 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 129.67, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.75. The company’s 50-day simple moving average is $39.01 and its 200-day simple moving average is $42.57.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.